Skip to content

C4X Discovery

Invested in:
Calculus EISs, Calculus VCT

C4X Discovery (C4XD) is a drug discovery and development company that uses cutting-edge technology to design and create drug candidates.

C4XD was spun out of the University of Manchester in July 2007. Their proprietary patented software, Conformetrix, allows scientists to view accurately the dynamic 3D shape of potential drug candidates on the basis of experimental data, and to select the candidate that is most likely to bind to the required target. Previously it was only possible to determine this in the laboratory, using time consuming and expensive trial and error techniques.

The company’s second patented software platform is Taxonomy3® which identifies novel genetic linkages by examining data sets on certain diseases allowing new drug targets to be identified. The Company have already had success in this area with Rheumatoid Arthritis and Parkinson’s disease.

C4XD’s licensed candidate, a non-opioid drug for the treatment of opioid use disorder, which has potential milestones for C4XD of up to a further $284m beyond the $10m payment received in 2018, progressed well with a US Government grant received to support its development and a CRO appointed to conduct Phase I trials.

There has been continued progress across C4XD’s proprietary portfolio of 11 drug discovery programmes in multiple therapeutic areas including neurodegeneration, oncology and immunology; and the partnering process for C4XD’s next key candidate, has launched with discussions to date confirming commercial interest in the candidate for the treatment of Sickle Cell Disease and Pulmonary Arterial Hypertension.


C4XD’s research is already making headway, with their drug candidate targeting addiction at the pre-clinical candidate stage. Addiction has historically been a difficult area for large companies as the receptors that cause addiction and drowsiness are virtually identical. C4X have identified a small molecule that is 1,000 fold more selective for the required addiction receptor where as others have previously failed in doing this. Other active projects include drug molecules targeting psoriasis, COPD and diabetes.

Calculus Capital was attracted both to C4XD’s experienced management team and their unique software platform. Funds will be used to progress C4XD’s existing pipeline of pre-clinical drug design and development for use in the treatment of a wide range of diseases and medical conditions.

Latest News

C4X Discovery’s CEO steps up as Interim Chair of UK Vaccine Taskforce

C4X Discovery Holdings plc, a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine.  The Government will set out arrangements … Continued

C4X teams up with PhoreMost to look for potential Parkinson’s treatments

Calculus Capital portfolio company C4X Discovery Holdings plc has teamed up with fellow UK-based biopharma, PhoreMost, to look for treatments for Parkinson’s Disease and other ‘undruggable’ diseases. The pair will take potentially useful compounds already identified by C4X’s Taxonomy 3 platform and run them through PhoreMost’s SITESEEKER screening platform. That data can then be exploited by … Continued

Horizon Discovery Group enters exclusive partnership with C4X Discovery Holdings

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc, a pioneering drug discovery company, to validate targets and develop next-generation oncology drugs. The partnership aims to validate the novel synthetic lethal … Continued

C4X awarded grant from the US National Institute on Drug Abuse (NIDA)

C4X recently announced that their C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an … Continued